Biology of adeno-associated viral vectors in the central nervous system
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Gene therapy is a promising approach for treating a spectrum of neurological and neurodegenerative disorders by delivering corrective genes to the central nervous system (CNS). In particular, adeno-associated viruses (AAVs) have emerged as promising tools for clinical gene transfer in a broad range of genetic disorders with neurological manifestations. In the current review, we have attempted to bridge our understanding of the biology of different AAV strains with their transduction profiles, cellular tropisms, and transport mechanisms within the CNS. Continued efforts to dissect AAV-host interactions within the brain are likely to aid in the development of improved vectors for CNS-directed gene transfer applications in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“…to perform extensive neuronal and glial transduction from different routes of injection in small and large animal models (Cearley and Wolfe, 2007; Foust et al., 2009; Bevan et al., 2011; Dayton et al., 2012; Ahmed et al., 2013; Benkhelifa-Ziyyat et al., 2013; Iwata et al., 2013; Yamashita et…”
MethodXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“AAV2, three and six bind heparan sulfate (HS) proteoglycans, whereas AAV9 requires N-terminal galactose residues to perform successful gene transfer (Summerford and Samulski, 1998; Handa et al., 2000; Bell et al., 2011; Shen et al., 2011).”
BackgroundSelf-citationClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology
Abbott, N. J. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2003.11.006 · Cited by 786
Rennels, M. L., Gregory, T. F., Blaumanis, O. R., Fujimoto, K., & Grady, P. A. (1985) · Brain Research · doi:10.1016/0006-8993(85)91383-6 · Cited by 752 · cited 1×
“One of the earliest studies demonstrated that proteins accumulate along highly vascularized regions of forebrain and brainstem within minutes of ICV injections (Rennels et al., 1985).”
BackgroundBurger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 9×
“In addition to these in vivo studies, biophysical analysis of the AAV4 capsid has revealed distinct structural features and low capsid homology among other natural AAV isolates (Padron et al., 2005; Govindasamy et al., 2006).”
InfluentialDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 1×
“The vector genomes subsequently require the host cellular machinery to carry out second strand synthesis, transcription and translation (Duan et al., 1998; Nash et al., 2008).”
BackgroundGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Self-citationIntegration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Self-citationGray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377 · cited 1×
“From studies conducted in large animals like pigs and non-human primates (NHPs), a single IT injection of AAV9 has emerged as the candidate procedure for clinical correction of motor neuron disorders affecting the different regions of the spinal cord (Federici et al., 2012; Gray et al., 2013).”
BackgroundBevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., Chan, C. M., McCrate, M., Chicoine, L. G., Coley, B. D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.157 · Cited by 337
Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 1×
“…into cerebral ventricles, cisterna magna, or intravertebral lumbar puncture (Davidson et al., 2000; Passini and Wolfe, 2001; Fu et al., 2003, 2007; Liu et al., 2005b; Cabrera-Salazar et al., 2010; Glascock et al., 2012; Rafi et al., 2012; Samaranch et al., 2012, 2013; Chakrabarty et al., 2013).”
BackgroundZhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291 · cited 8×
“For instance, using directed evolution, Gray et al. (2010) have engineered two AAV capsids capable of crossing seizure compromised-BBB in rats.”
BackgroundInfluentialChamberlin, N. L., Du, B., de Lacalle, S., & Saper, C. B. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00169-3 · Cited by 221 · cited 1×
“Direct injections of AAV into the CNS have been used to achieve high levels of transgene expression across different animal models (McCown et al., 1996; Chamberlin et al., 1998; Tenenbaum et al., 2004; Bockstael et al., 2012).”
MethodAAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215 · cited 2×
“Different AAV serotypes exhibit a range of properties pertaining to antigenicity, in vivo tropism and receptor interactions based on their capsid structures (Agbandje-McKenna and Kleinschmidt, 2011).”
BackgroundYang, B., Li, S., Wang, H., Guo, Y., Gessler, D. J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S. S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.68 · Cited by 213 · cited 4×
“Another study in marmosets demonstrated that IV administration of AAVrh.10 is capable of efficient CNS transduction (Yang et al., 2014).”
BackgroundInfluentialStructurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205 · cited 1×
“In addition to these in vivo studies, biophysical analysis of the AAV4 capsid has revealed distinct structural features and low capsid homology among other natural AAV isolates (Padron et al., 2005; Govindasamy et al., 2006).”
BackgroundThe AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G.-P., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57367 · Cited by 190
Passini, M. A., & Wolfe, J. H. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12382-12392.2001 · Cited by 185 · cited 1×
“…the CNS has been achieved using AAV injections into cerebral ventricles, cisterna magna, or intravertebral lumbar puncture (Davidson et al., 2000; Passini and Wolfe, 2001; Fu et al., 2003, 2007; Liu et al., 2005b; Cabrera-Salazar et al., 2010; Glascock et al., 2012; Rafi et al., 2012; Samaranch…”
BackgroundGray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185 · cited 3×
“For instance, using directed evolution, Gray et al. (2010) have engineered two AAV capsids capable of crossing seizure compromised-BBB in rats.”
BackgroundSelf-citationExpanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain
Cearley, C. N., Vandenberghe, L. H., Parente, M. K., Carnish, E. R., Wilson, J. M., & Wolfe, J. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.166 · Cited by 182
Sondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., Wilson, J. M., & Crystal, R. G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300049 · Cited by 170 · cited 1×
“AAV2, three and six bind heparan sulfate (HS) proteoglycans, whereas AAV9 requires N-terminal galactose residues to perform successful gene transfer (Summerford and Samulski, 1998; Handa et al., 2000; Bell et al., 2011; Shen et al., 2011).”
BackgroundAxonal transport of adeno-associated viral vectors is serotype-dependent
Salegio, E. A., Samaranch, L., Kells, A. P., Mittermeyer, G., San Sebastian, W., Zhou, S., Beyer, J., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2012.27 · Cited by 156
Tailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155 · cited 1×
“AAV serotypes 1, 5, 8, and 9 have shown extensive transduction in the spinal cord and DRG neurons from IT injections at the intravertebral lumbar region (Vulchanova et al., 2010; Hirai et al., 2012; Jacques et al., 2012).”
The advent of AAV9 expands applications for brain and spinal cord gene delivery
Dayton, R. D., Wang, D. B., & Klein, R. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681463 · Cited by 144 · cited 1×
“…extensive neuronal and glial transduction from different routes of injection in small and large animal models (Cearley and Wolfe, 2007; Foust et al., 2009; Bevan et al., 2011; Dayton et al., 2012; Ahmed et al., 2013; Benkhelifa-Ziyyat et al., 2013; Iwata et al., 2013; Yamashita et al., 2013).”
BackgroundInsertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K. (2009) · Journal of Virology · doi:10.1128/jvi.01865-08 · Cited by 138
Ciesielska, A., Hadaczek, P., Mittermeyer, G., Zhou, S., Wright, J. F., Bankiewicz, K. S., & Forsayeth, J. (2013) · Molecular Therapy · doi:10.1038/mt.2012.167 · Cited by 108
McCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J., & Fu, H. (2009) · Gene Therapy · doi:10.1038/gt.2009.85 · Cited by 105
Hadaczek, P., Forsayeth, J., Mirek, H., Munson, K., Bringas, J., Pivirotto, P., L McBride, J., Davidson, B. L., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.151 · Cited by 90
Liu, G., Martins, I. H., Chiorini, J. A., & Davidson, B. L. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302554 · Cited by 84
Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain
San Sebastian, W., Samaranch, L., Heller, G., Kells, A. P., Bringas, J., Pivirotto, P., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.48 · Cited by 62 · cited 1×
“On the other hand, AAV6 exhibits exclusive retrograde transport in both rat and primate brain (San Sebastian et al., 2013).”
BackgroundRosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58 · cited 2×
“For instance, recent studies in the primate brain have demonstrated that AAVrh.10 displays distinct transduction patterns following different routes of administration (Rosenberg et al., 2014).”
Background
Cited by
A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons
Tervo, D. G. R., Hwang, B.-Y., Viswanathan, S., Gaj, T., Lavzin, M., Ritola, K. D., Lindo, S., Michael, S., Kuleshova, E., Ojala, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.021 · Cited by 1,179
Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease
Tabrizi, S. J., Ghosh, R., & Leavitt, B. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.039 · Cited by 337
Pearn, M. L., Niesman, I. R., Egawa, J., Sawada, A., Almenar-Queralt, A., Shah, S. B., Duckworth, J. L., & Head, B. P. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0400-1 · Cited by 296
Applications of CRISPR–Cas systems in neuroscience
Heidenreich, M., & Zhang, F. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.2 · Cited by 283
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Metadata
- Authors
- Murlidharan, G., Samulski, R. J., & Asokan, A.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-09-19
- Volume
- 7
- Pages
- 76-76
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W1989073393
- Cited by
- 154
- References
- 34
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.